Progress in the clinical development of CX-2051, targeted at advanced colorectal cancer, with initial Phase 1a clinical data expected in the first half of 2025. CytomX maintains a strong financial ...
CytomX Therapeutics has updated its pipeline priorities for 2025, highlighting its lead program, CX-2051, a first-in-class PROBODY ADC targeting EpCAM for advanced metastatic colorectal cancer, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results